ERAS · Erasca Inc. Common Stock
View on chartInsiders & Stakes
| Lim Jonathan E Chairman & CEO | ▲ Buy | Open Market | 12,899,360 Shares held | 12/6/2023 | View profile |
| Bihua Chen Chairperson and CEO | ▲ Buy | Open Market | 10,813,246 Shares held | 12/13/2022 | View profile |
| Casdin Alexander W. Director | ▲ Buy | Open Market | 573,974 Shares held | 5/21/2024 | View profile |
| Lin Wei Chief Medical Officer | ▼ Sell | Other | 315,812 Shares held | 2/1/2023 | View profile |
| Chacko David M. Chief Financial Officer | ▼ Sell | Other | 279,980 Shares held | 12/15/2025 | View profile |
| Garner Ebun General Counsel & Corp. Sec. | ▼ Sell | Open Market | 25,076 Shares held | 4/1/2026 | View profile |
| Start Valerie Denise Harding Director | ▲ Buy | Open Market | 20,000 Shares held | 12/6/2023 | View profile |
| Bristol James Arthur Director | ▲ Buy | Open Market | 20,000 Shares held | 12/21/2022 | View profile |
| Multani Pratik S Chief Medical Officer | ▼ Sell | Gift | 6,200 Shares held | 5/23/2025 | View profile |
| Morris Shannon Chief Medical Officer | ▼ Sell | Open Market | 0 Shares held | 3/4/2026 | View profile |
Transaction History
| Garner Ebun | ▲ Buy | Option Exercise | 80,000 | $136K | 4/1/2026 |
| Garner Ebun | ▼ Sell | Open Market | 80,000 | $1.3M | 4/1/2026 |
| Morris Shannon | ▲ Buy | Option Exercise | 20,000 | $34K | 3/4/2026 |
| Morris Shannon | ▼ Sell | Open Market | 20,000 | $301K | 3/4/2026 |
| Garner Ebun | ▲ Buy | Option Exercise | 120,000 | $204K | 1/7/2026 |
| Garner Ebun | ▼ Sell | Open Market | 120,000 | $671K | 1/7/2026 |
| Chacko David M. | ▼ Sell | Other | 17,793 | $21K | 12/15/2025 |
| Garner Ebun | ▲ Buy | Grant | 3,902 | $5K | 12/15/2025 |
| Multani Pratik S | ▼ Sell | Gift | 6,200 | $0 | 5/23/2025 |
| Multani Pratik S | ▼ Sell | Gift | 6,200 | $0 | 5/23/2025 |
| Chacko David M. | ▼ Sell | Other | 12,324 | $19K | 12/13/2024 |
| Garner Ebun | ▼ Sell | Other | 5,731 | $9K | 12/13/2024 |
| Chacko David M. | ▼ Sell | Other | 3,137 | $5K | 6/14/2024 |
| Garner Ebun | ▼ Sell | Other | 5,715 | $9K | 6/14/2024 |
| Casdin Alexander W. | ▲ Buy | Open Market | 80,000 | $182K | 5/21/2024 |
| Chacko David M. | ▼ Sell | Other | 7,478 | $12K | 12/15/2023 |
| Garner Ebun | ▼ Sell | Other | 5,448 | $9K | 12/15/2023 |
| Start Valerie Denise Harding | ▲ Buy | Open Market | 10,000 | $18K | 12/6/2023 |
| Lim Jonathan E | ▲ Buy | Open Market | 278,150 | $478K | 12/6/2023 |
| Lim Jonathan E | ▲ Buy | Open Market | 721,850 | $1.2M | 12/5/2023 |
| Casdin Alexander W. | ▲ Buy | Open Market | 30,000 | $50K | 12/4/2023 |
| Lim Jonathan E | ▲ Buy | Open Market | 1,000,000 | $2.0M | 10/5/2023 |
| Lim Jonathan E | ▲ Buy | Open Market | 100,000 | $275K | 6/8/2023 |
| Casdin Alexander W. | ▲ Buy | Open Market | 20,000 | $55K | 4/10/2023 |
| Lim Jonathan E | ▲ Buy | Open Market | 100,000 | $284K | 3/28/2023 |
| Chacko David M. | ▼ Sell | Other | 1,748 | $7K | 2/1/2023 |
| Chacko David M. | ▼ Sell | Other | 2 | $8 | 2/1/2023 |
| Lin Wei | ▼ Sell | Other | 1,748 | $7K | 2/1/2023 |
| Lin Wei | ▼ Sell | Other | 2 | $8 | 2/1/2023 |
| Garner Ebun | ▼ Sell | Other | 2,388 | $10K | 2/1/2023 |
| Garner Ebun | ▼ Sell | Other | 2 | $8 | 2/1/2023 |
| Lim Jonathan E | ▲ Buy | Open Market | 60,000 | $231K | 1/10/2023 |
| Bristol James Arthur | ▲ Buy | Open Market | 20,000 | $83K | 12/21/2022 |
| Start Valerie Denise Harding | ▲ Buy | Open Market | 10,000 | $46K | 12/21/2022 |
| Casdin Alexander W. | ▲ Buy | Open Market | 20,000 | $97K | 12/15/2022 |
| Lim Jonathan E | ▲ Buy | Open Market | 40,000 | $200K | 12/14/2022 |
| Bihua Chen | ▲ Buy | Open Market | 307,692 | $2.0M | 12/13/2022 |
| Casdin Alexander W. | ▼ Sell | Other | 750,000 | $0 | 7/1/2022 |
| Garner Ebun | ▼ Sell | Other | 990 | $11K | 2/1/2022 |
| Lin Wei | ▼ Sell | Other | 1,562 | $18K | 2/1/2022 |
| Chacko David M. | ▼ Sell | Other | 1,562 | $18K | 2/1/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates
Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.